Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ALXO 
Alx Oncology Holdings (ALXO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/21/2025: ALXO (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $2.67
1 Year Target Price $2.67
| 3 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 159.12% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/21/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 88.36M USD | Price to earnings Ratio - | 1Y Target Price 2.67 |
Price to earnings Ratio - | 1Y Target Price 2.67 | ||
Volume (30-day avg) 6 | Beta 1.22 | 52 Weeks Range 0.40 - 2.27 | Updated Date 10/21/2025 |
52 Weeks Range 0.40 - 2.27 | Updated Date 10/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.38 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -47.78% | Return on Equity (TTM) -104.21% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 33008665 | Price to Sales(TTM) 5906.24 |
Enterprise Value 33008665 | Price to Sales(TTM) 5906.24 | ||
Enterprise Value to Revenue 4254.36 | Enterprise Value to EBITDA -2.35 | Shares Outstanding 53551134 | Shares Floating 28805155 |
Shares Outstanding 53551134 | Shares Floating 28805155 | ||
Percent Insiders 2.75 | Percent Institutions 72.51 |
Upturn AI SWOT
Alx Oncology Holdings
Company Overview
History and Background
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company focused on developing therapies that block the CD47 checkpoint pathway. Founded in 2015, it has rapidly progressed its lead candidate, ALX148, through clinical trials.
Core Business Areas
- CD47 Checkpoint Inhibition: Developing ALX148 and other therapies targeting the CD47/SIRPu03b1 pathway to enhance anti-tumor immunity.
Leadership and Structure
The leadership team includes Sophia Randolph, M.D., Ph.D. (CEO), and other experienced professionals in oncology drug development. The company has a board of directors and operates with a focus on research and clinical development.
Top Products and Market Share
Key Offerings
- ALX148: A CD47 blocker in clinical trials for various cancers, including head and neck squamous cell carcinoma (HNSCC). Market share is currently N/A (clinical stage). Competitors include companies developing similar CD47 inhibitors, such as Forty Seven (GILD), and Trillium Therapeutics (acquired by Pfizer).
Market Dynamics
Industry Overview
The immuno-oncology market is rapidly growing, with significant interest in checkpoint inhibitors. CD47 is a key target in this field.
Positioning
ALX Oncology is positioned as a key player in the CD47 checkpoint inhibitor space, with a focus on developing differentiated therapies.
Total Addressable Market (TAM)
The TAM for CD47-targeted therapies is estimated to be billions of dollars, depending on the success of clinical trials and regulatory approvals. ALX Oncology is positioned to capture a significant share if ALX148 is approved.
Upturn SWOT Analysis
Strengths
- Promising clinical data for ALX148
- Experienced management team
- Strong intellectual property position
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- High clinical development risk
- Reliance on a single lead candidate (ALX148)
Opportunities
- Potential partnerships with larger pharmaceutical companies
- Expansion into new cancer indications
- Development of next-generation CD47 inhibitors
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other CD47 inhibitors and immuno-oncology therapies
Competitors and Market Share
Key Competitors
- GILD
- PFE
Competitive Landscape
ALX Oncology competes with other companies developing CD47 inhibitors. Their differentiated approach to blocking CD47 may offer advantages.
Growth Trajectory and Initiatives
Historical Growth: Growth is primarily driven by clinical development progress and potential partnerships.
Future Projections: Future growth depends on the success of ALX148 clinical trials and potential regulatory approvals.
Recent Initiatives: Focus on enrolling and advancing the ongoing ALX148 clinical trials, and expanding clinical scope of molecule to different solid tumors.
Summary
Alx Oncology is a clinical-stage company focused on CD47 checkpoint inhibition and the clinical success of their lead product. While it has promising technology, it faces substantial clinical development risk. Positive clinical trial results and strategic partnerships are necessary for significant growth. Its current lack of revenue and reliance on investment require careful financial management.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Clinical trial data
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data and analysis are based on publicly available information and are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alx Oncology Holdings
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2020-07-17 | CEO & Director Mr. Jason W. Lettmann | ||
Sector Healthcare | Industry Biotechnology | Full time employees 49 | Website https://www.alxoncology.com |
Full time employees 49 | Website https://www.alxoncology.com | ||
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Symposium; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.